JPWO2020181182A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020181182A5 JPWO2020181182A5 JP2021552582A JP2021552582A JPWO2020181182A5 JP WO2020181182 A5 JPWO2020181182 A5 JP WO2020181182A5 JP 2021552582 A JP2021552582 A JP 2021552582A JP 2021552582 A JP2021552582 A JP 2021552582A JP WO2020181182 A5 JPWO2020181182 A5 JP WO2020181182A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cedna vector
- vector
- item
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 40
- 108020004414 DNA Proteins 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 30
- -1 modified dexamethasone compound Chemical class 0.000 claims description 23
- 241000238631 Hexapoda Species 0.000 claims description 19
- 108700019146 Transgenes Proteins 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 13
- 230000037361 pathway Effects 0.000 claims description 12
- 238000012217 deletion Methods 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 10
- 230000037431 insertion Effects 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 claims description 4
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 claims description 4
- 108010034143 Inflammasomes Proteins 0.000 claims description 4
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 4
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 4
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229950000812 dexamethasone palmitate Drugs 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 108091026890 Coding region Proteins 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 210000000234 capsid Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000015788 innate immune response Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000008088 immune pathway Effects 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims 12
- 238000003936 denaturing gel electrophoresis Methods 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814477P | 2019-03-06 | 2019-03-06 | |
| US62/814,477 | 2019-03-06 | ||
| PCT/US2020/021367 WO2020181182A1 (en) | 2019-03-06 | 2020-03-06 | Closed-ended dna (cedna) and immune modulating compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523806A JP2022523806A (ja) | 2022-04-26 |
| JP2022523806A5 JP2022523806A5 (https=) | 2023-03-14 |
| JPWO2020181182A5 true JPWO2020181182A5 (https=) | 2023-03-14 |
Family
ID=72337625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552582A Pending JP2022523806A (ja) | 2019-03-06 | 2020-03-06 | 閉端ｄｎａ（ｃｅｄｎａ）および免疫調節化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220184231A1 (https=) |
| EP (1) | EP3934701A4 (https=) |
| JP (1) | JP2022523806A (https=) |
| AU (1) | AU2020231228A1 (https=) |
| CA (1) | CA3132164A1 (https=) |
| IL (1) | IL286031A (https=) |
| MA (1) | MA55223A (https=) |
| SG (1) | SG11202108864UA (https=) |
| WO (1) | WO2020181182A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202545984A (zh) | 2017-08-09 | 2025-12-01 | 美商生物化學醫療公司 | 核酸分子及其用途 |
| WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| CN116234917A (zh) | 2020-07-27 | 2023-06-06 | 安杰瑞姆生物科学公司 | Dna分子组合物及其制备方法和使用方法 |
| WO2025114932A1 (en) * | 2023-11-30 | 2025-06-05 | Sanofi | Purification of closed-ended dna molecules |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| CA2975371C (en) * | 2015-01-30 | 2024-02-13 | Nof Corporation | Cationic lipid for nucleic acid delivery |
| JP7014721B2 (ja) * | 2015-09-18 | 2022-02-01 | ディーエヌエーアールエックス | インビボでの核酸発現のためのシステム及び方法 |
| GB2547179A (en) * | 2015-10-26 | 2017-08-16 | Quethera Ltd | Genetic construct |
| WO2017152149A1 (en) * | 2016-03-03 | 2017-09-08 | University Of Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
| CN109983129A (zh) * | 2016-11-23 | 2019-07-05 | 柏林制药股份有限公司 | 用于抑制和/或压制tlr9激活的适体 |
| WO2018237369A2 (en) * | 2017-06-23 | 2018-12-27 | Vical Incorporated | Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection |
-
2020
- 2020-03-06 CA CA3132164A patent/CA3132164A1/en active Pending
- 2020-03-06 AU AU2020231228A patent/AU2020231228A1/en active Pending
- 2020-03-06 WO PCT/US2020/021367 patent/WO2020181182A1/en not_active Ceased
- 2020-03-06 JP JP2021552582A patent/JP2022523806A/ja active Pending
- 2020-03-06 EP EP20767207.2A patent/EP3934701A4/en active Pending
- 2020-03-06 US US17/435,419 patent/US20220184231A1/en active Pending
- 2020-03-06 SG SG11202108864UA patent/SG11202108864UA/en unknown
- 2020-03-06 MA MA055223A patent/MA55223A/fr unknown
-
2021
- 2021-09-01 IL IL286031A patent/IL286031A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12134770B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12281309B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| WO2024079667A1 (en) | Nucleic acid regulatory elements for gene expression in the central nervous system and methods of use | |
| US20250163463A1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| JPWO2020181182A5 (https=) | ||
| EP4527933A1 (en) | Dual-carrier system for treating hearing damage, and use thereof | |
| US12416020B2 (en) | Plasmid encoding a TLR3 and Fc fusion protein | |
| US12497618B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12281315B1 (en) | Composition for regulating production of proteins | |
| US12516332B2 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12503697B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12428654B1 (en) | Composition for regulating production of proteins | |
| US12480129B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12263232B1 (en) | Composition for regulating production of proteins | |
| US12281311B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12264329B1 (en) | Composition for regulating production of fusion proteins | |
| US12486506B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12480123B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12281325B1 (en) | Composition for regulating production of proteins | |
| US12338452B1 (en) | Compositions for regulating production of an antibody like protein and ribonucleic acid | |
| US12351835B1 (en) | Composition for regulating production of proteins | |
| US12416021B1 (en) | Composition for regulating production of proteins | |
| WO2024257061A1 (en) | A hybrid dual aav vector system with splice enhancer elements for expression of large genes | |
| US20250263723A1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| RU2023131775A (ru) | Композиции и способы лечения сенсоневральной тугоухости с применением стереоцилиновых двухвекторных систем |